Besponsa 0.9 mg (Inotuzumab Ozogamicin POWDER FOR SOLUTION) 0.9 MG

Bespansa 0.9 mg is a powder for solution used in intravenous therapy. This medication, containing inotuzumab ozogamicin, is designed for targeted treatment in specific medical conditions. Learn more about its uses and effects.

Strength

0.9 MG

Manufacturer / TM Owner

PFIZER CANADA ULC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Bespansa 0.9 mg is primarily used for targeted therapy in certain types of cancer. It works by attaching to specific cells and delivering a cytotoxic agent. This process helps in reducing the proliferation of targeted cells. Patients often wonder, 'What is Bespansa used for?' It is typically prescribed for conditions where targeted cell destruction is beneficial.

Side Effects

Common effects of Bespansa 0.9 mg may include fatigue, fever, and nausea. Some patients also experience infusion-related reactions. These effects can vary widely among individuals. Always consult a healthcare provider for personalized information.

Precautions & Warnings

Bespansa 0.9 mg should be handled with care. It is important to follow proper storage and administration guidelines. Patients with certain medical conditions or allergies should inform their healthcare provider before use. Always use under medical supervision.

Avoid Interactions

Bespansa 0.9 mg may interact with other medications, including those that affect the immune system. It is advisable to discuss all current medications with a healthcare provider. Avoid alcohol and other substances that may compromise treatment efficacy.

Frequently Asked Questions

Bespansa 0.9 mg is used for targeted therapy in specific types of cancer. It works by attaching to certain cells and delivering a cytotoxic agent.

Bespansa 0.9 mg is administered intravenously as a powder for solution. It should be prepared and administered by healthcare professionals.

Common side effects may include fatigue, fever, nausea, and infusion-related reactions. Always consult a healthcare provider for detailed information.

Bespansa 0.9 mg may interact with other medications. It is important to discuss all current medications with a healthcare provider before starting treatment.

Patients with certain medical conditions or allergies should inform their healthcare provider before using Bespansa 0.9 mg. Always use under medical supervision.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.